Category: Research

FSR Well-Represented at SCOPE 2017

FSR Well-Represented at SCOPE 2017

FSR’s Ginger Spitzer will be presenting at the 8th annual Summit for Clinical Ops Executives, or SCOPE in Miami, FL later this month. SCOPE is a 3-day summit of conferences, workshops and symposiums, all dedicated to productive and in-depth conversations the...
Baltimore Clinical Trial for Neurosarcoidosis Patients

Baltimore Clinical Trial for Neurosarcoidosis Patients

For all neurosarcoidosis patients, a clinical trial in the Baltimore area entitled, “Clinical Biomarkers of Disease Activity and Treatment Response in Patients with CNS Sarcoidosis Treated with H.P. Acthar Gel”, is now open for recruitment specifically to patients in...
Hospitals start comparing health outcomes internationally

Hospitals start comparing health outcomes internationally

A new collaboration between six hospitals around the world is allowing doctors to exchange data and compare case outcomes, in order to establish best practices when it comes to treating sarcoidosis. The press release announcement is below: Nieuwegein / Utrecht, 13...
San Francisco Research Studies Looking for Participants

San Francisco Research Studies Looking for Participants

UCSF Sarcoidosis Studies are Recruiting! San Francisco based studies are looking for people diagnosed with sarcoidosis in or near the bay area to join us in learning more about this disease. All studies are currently observational (no interventions), looking closely...
Clinical Trial for Patients with Pulmonary Hypertension

Clinical Trial for Patients with Pulmonary Hypertension

As a patient battling sarcoidosis and/or pulmonary hypertension, you already know the frustration of limited treatment options.  The Foundation of Sarcoidosis Research is by your side in this fight, dedicated to providing resources to patients as well as working with...
SAKURA Phase III Study

SAKURA Phase III Study

The SAKURA study is a Phase III, multinational, double-masked trial investigating the safety and efficacy of DE-109 for the treatment of non-infectious uveitis of the posterior segment.  DE-109 is a proprietary formulation of sirolimus that is an anti-inflammatory...